Canaccord Starts Eton Pharmaceuticals (ETON) at Buy

Canaccord analyst Gary Newman initiates coverage on Eton Pharmaceuticals (NASDAQ: ETON) with a Buy rating and a price target of $60.00.

For an analyst ratings summary and ratings history on Eton Pharmaceuticals click here. For more ratings news on Eton Pharmaceuticals click here.

Shares of Eton Pharmaceuticals closed at $38.50 yesterday.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• USA Rare Earth (USAR) files for 126.5M share offering by selling stockholders
• Stardust Solar plans $641K convertible debenture private placement